Market Cap 35.54M
Revenue (ttm) 0.00
Net Income (ttm) -80.65M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,846,270
Avg Vol 1,341,852
Day's Range N/A - N/A
Shares Out 172.12M
Stochastic %K 7%
Beta 0.54
Analysts Strong Buy
Price Target N/A

Company Profile

Lunai Bioworks Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands. It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops...

Industry: Biotechnology
Sector: Healthcare
Phone: 305 918 1980
Address:
2080 Century Park East, Suite 906, Los Angeles, United States
Paul_Jones
Paul_Jones Sep. 12 at 2:57 PM
$RENB is thinly traded, while AITX is actively scaling deployments to hit profitability targets.
0 · Reply
MarketForecasting
MarketForecasting Sep. 12 at 1:27 PM
$RENB I thought the company was doing well long before the scammish name change , obviously that was a lie along with the next lie you tell .
0 · Reply
Nottrue
Nottrue Sep. 12 at 5:44 AM
$RENB Stengaard has a long rhetoric and has been an avid promoter of Renovaro. Lunai Bioworks is now moving into a new direction and that could be good if there was a strong leadership.Hopefully they will find a new Chairperson tha thas makret and investment banking knowledge.Then USA centric investors will come in.That has to happen quickly or the company will flounder .The lack of communication is killing.
0 · Reply
Nottrue
Nottrue Sep. 12 at 5:29 AM
$RENB It is unfortunate but all really superb news seems to fall to deeaf ears. Renovaro has re-invented themselves to Lunai Bioworks and thereby discarded teh tainted Sehrat past.There is no more bio and his bogus discoveries which were not novel.Anahid Jewett whom they applauded with was focussing her efforts on Nkore and NK cells ,under the supervision of the old Chairman(spindles) bogus annoumcents were made and worse as chair he promised share prices that were unrealistic. The new board decided to follow MAGA which is fine making the company more USA centric hence the departure of Maurice v Tilburg. Now they need a new Chair someone that knows the markets and the investment banks ,they also need a CEO that communicates and addresses the markets not only there for self preservation. The direction of the company appealing to USA defense is a good one and Biosymetrics in itself should bring the share price to 2 per share.Tine for stronger leadership at Lunai Bioworks.
0 · Reply
Stengaard1
Stengaard1 Sep. 11 at 8:26 PM
$RENB, a fellow contributor called Renovaro (in a private message) - a short seller's ultimate dream... And to some extent (almost close to 100%) he has been right - even (or rather in particular) when the company send out good news, it is being picked up and used to sell... Why? Because the company presently does not have enough strong supportive shareholders or institutions that can flex some buying power. I.o.w., right now the Danes have almost lost patience, and there are no Dutch buyers either. That leaves us with the Americans as new investors, and Lunai have zero-zilch-nada-no appeal or presence there, partly because of the Serhat debacle (still partially unresolved) and the TOTAL absence of Investor Relations, Market Makers, Road-Shows or ANY awareness creating activity that Top-Management should have as priority Today is no exception :) Lunai gets a Governmental grant, news gets sent out on an obscure website . Although it is a relatively small grant 1.85 million USD - it is cash and validation - and the result is an even lower price ... This is not going to change until we see some serious grants (i.e. a/more years' cash burn or more) or some significant partnerships that bring in some muscles :) or - hopefully both. The last months have seen a focus on: Securing vital AI-patents with groundbreaking potential (Biosymetrics hold close to 50% of all AI-related patents in the predictive area. Still, the price has gone down. Biosymetrics has a world-class zebra-fish model with enormous potential (one of the few specimens where you do not have to kill the host to measure the results). Still, the price has gone down Regrouping and refocusing the organisation, strengthening core and reducing costs by concentrating forces in the US, making the company more appealing to the US Government, where the "America First" Agenda defines all. Still, the price had gone down Very interesting cooperation with one of the most influential defence lobby organisations in the US, with very strong ties to the Republican Party. Still, the price has gone down Unfortunately, I do not see this changing unless the company attracts someone who can really raise awareness and money,- because it certainly is not good news, brilliant research, or intriguing new products that we lack. BUT once/if they do that, then there are so many good things that from just that last couple of months (on top of UMC e.t.c.) that have not been priced in.
0 · Reply
Stengaard1
Stengaard1 Sep. 11 at 4:13 PM
$RENB first minor grant - but a significant step https://www.morningstar.com/news/accesswire/1071666msn/lunai-bioworks-subsidiary-biosymetrics-and-brigham-and-womens-hospital-awarded-nih-sttr-grant-to-develop-ai-powered-platform-for-alcohol-use-disorder-therapeutics
1 · Reply
Yassin_tet
Yassin_tet Sep. 11 at 3:39 PM
$RENB really???
0 · Reply
Nottrue
Nottrue Sep. 11 at 3:35 PM
$RENB Biosymmetrics is a very good copany and the direction the group is moving in is extremely promising but with this low share price not much can be activated I fear.Difficult to uderstand tha tpeople are not buying a thtis low price and with all hte positive press.
0 · Reply
Pnmoltke
Pnmoltke Sep. 11 at 2:38 PM
$RENB Gedi Cube B.V. which Renovaro (Lunai Bioworks) have bought was declared bankrupt on September 2, 2025 in Amsterdam…Not good…
0 · Reply
MarketForecasting
MarketForecasting Sep. 11 at 1:37 PM
$RENB Fake Ghost Company (FGC), should be the new ticker name .
0 · Reply
Latest News on RENB
Top 3 Health Care Stocks You'll Regret Missing In Q3

Sep 9, 2025, 9:12 AM EDT - 5 days ago

Top 3 Health Care Stocks You'll Regret Missing In Q3

CERO SMMT


Lunai Bioworks Inc. Retains American Defense International

Sep 4, 2025, 10:05 AM EDT - 10 days ago

Lunai Bioworks Inc. Retains American Defense International


Renovaro Announces $15 million in Equity Committed

Feb 26, 2025, 9:15 AM EST - 7 months ago

Renovaro Announces $15 million in Equity Committed


Renovaro Appoints Nathen Fuentes as Chief Financial Officer

Jan 7, 2025, 9:15 AM EST - 8 months ago

Renovaro Appoints Nathen Fuentes as Chief Financial Officer


Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV

Dec 30, 2024, 9:00 AM EST - 9 months ago

Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV


Renovaro Regains Compliance with NASDAQ Listing Requirement

Dec 20, 2024, 3:40 PM EST - 9 months ago

Renovaro Regains Compliance with NASDAQ Listing Requirement


Renovaro, Inc. Announces $10 million in Equity Committed

Jun 14, 2024, 9:06 AM EDT - 1 year ago

Renovaro, Inc. Announces $10 million in Equity Committed


Statement of Renovaro Inc

Feb 14, 2024, 10:01 AM EST - 1 year ago

Statement of Renovaro Inc


Message from Renovaro Biosciences CEO, The Hon. Mark Dybul, MD

Oct 2, 2023, 12:05 PM EDT - 2 years ago

Message from Renovaro Biosciences CEO, The Hon. Mark Dybul, MD


Paul_Jones
Paul_Jones Sep. 12 at 2:57 PM
$RENB is thinly traded, while AITX is actively scaling deployments to hit profitability targets.
0 · Reply
MarketForecasting
MarketForecasting Sep. 12 at 1:27 PM
$RENB I thought the company was doing well long before the scammish name change , obviously that was a lie along with the next lie you tell .
0 · Reply
Nottrue
Nottrue Sep. 12 at 5:44 AM
$RENB Stengaard has a long rhetoric and has been an avid promoter of Renovaro. Lunai Bioworks is now moving into a new direction and that could be good if there was a strong leadership.Hopefully they will find a new Chairperson tha thas makret and investment banking knowledge.Then USA centric investors will come in.That has to happen quickly or the company will flounder .The lack of communication is killing.
0 · Reply
Nottrue
Nottrue Sep. 12 at 5:29 AM
$RENB It is unfortunate but all really superb news seems to fall to deeaf ears. Renovaro has re-invented themselves to Lunai Bioworks and thereby discarded teh tainted Sehrat past.There is no more bio and his bogus discoveries which were not novel.Anahid Jewett whom they applauded with was focussing her efforts on Nkore and NK cells ,under the supervision of the old Chairman(spindles) bogus annoumcents were made and worse as chair he promised share prices that were unrealistic. The new board decided to follow MAGA which is fine making the company more USA centric hence the departure of Maurice v Tilburg. Now they need a new Chair someone that knows the markets and the investment banks ,they also need a CEO that communicates and addresses the markets not only there for self preservation. The direction of the company appealing to USA defense is a good one and Biosymetrics in itself should bring the share price to 2 per share.Tine for stronger leadership at Lunai Bioworks.
0 · Reply
Stengaard1
Stengaard1 Sep. 11 at 8:26 PM
$RENB, a fellow contributor called Renovaro (in a private message) - a short seller's ultimate dream... And to some extent (almost close to 100%) he has been right - even (or rather in particular) when the company send out good news, it is being picked up and used to sell... Why? Because the company presently does not have enough strong supportive shareholders or institutions that can flex some buying power. I.o.w., right now the Danes have almost lost patience, and there are no Dutch buyers either. That leaves us with the Americans as new investors, and Lunai have zero-zilch-nada-no appeal or presence there, partly because of the Serhat debacle (still partially unresolved) and the TOTAL absence of Investor Relations, Market Makers, Road-Shows or ANY awareness creating activity that Top-Management should have as priority Today is no exception :) Lunai gets a Governmental grant, news gets sent out on an obscure website . Although it is a relatively small grant 1.85 million USD - it is cash and validation - and the result is an even lower price ... This is not going to change until we see some serious grants (i.e. a/more years' cash burn or more) or some significant partnerships that bring in some muscles :) or - hopefully both. The last months have seen a focus on: Securing vital AI-patents with groundbreaking potential (Biosymetrics hold close to 50% of all AI-related patents in the predictive area. Still, the price has gone down. Biosymetrics has a world-class zebra-fish model with enormous potential (one of the few specimens where you do not have to kill the host to measure the results). Still, the price has gone down Regrouping and refocusing the organisation, strengthening core and reducing costs by concentrating forces in the US, making the company more appealing to the US Government, where the "America First" Agenda defines all. Still, the price had gone down Very interesting cooperation with one of the most influential defence lobby organisations in the US, with very strong ties to the Republican Party. Still, the price has gone down Unfortunately, I do not see this changing unless the company attracts someone who can really raise awareness and money,- because it certainly is not good news, brilliant research, or intriguing new products that we lack. BUT once/if they do that, then there are so many good things that from just that last couple of months (on top of UMC e.t.c.) that have not been priced in.
0 · Reply
Stengaard1
Stengaard1 Sep. 11 at 4:13 PM
$RENB first minor grant - but a significant step https://www.morningstar.com/news/accesswire/1071666msn/lunai-bioworks-subsidiary-biosymetrics-and-brigham-and-womens-hospital-awarded-nih-sttr-grant-to-develop-ai-powered-platform-for-alcohol-use-disorder-therapeutics
1 · Reply
Yassin_tet
Yassin_tet Sep. 11 at 3:39 PM
$RENB really???
0 · Reply
Nottrue
Nottrue Sep. 11 at 3:35 PM
$RENB Biosymmetrics is a very good copany and the direction the group is moving in is extremely promising but with this low share price not much can be activated I fear.Difficult to uderstand tha tpeople are not buying a thtis low price and with all hte positive press.
0 · Reply
Pnmoltke
Pnmoltke Sep. 11 at 2:38 PM
$RENB Gedi Cube B.V. which Renovaro (Lunai Bioworks) have bought was declared bankrupt on September 2, 2025 in Amsterdam…Not good…
0 · Reply
MarketForecasting
MarketForecasting Sep. 11 at 1:37 PM
$RENB Fake Ghost Company (FGC), should be the new ticker name .
0 · Reply
paok44
paok44 Sep. 11 at 12:32 PM
$RENB https://finviz.com/news/163442/lunai-bioworks-subsidiary-biosymetrics-and-brigham-and-womens-hospital-awarded-nih-sttr-grant-to-develop-ai-powered-platform-for-alcohol-use-disorder-therapeutics
0 · Reply
paok44
paok44 Sep. 11 at 12:23 PM
$RENB https://www.gurufocus.com/news/3104143/innovative-ai-platform-for-drug-discovery-supported-by-nih-grant?utm_source=marketwatch&utm_medium=syndication&utm_campaign=headlines&r=4bf001661e6fdd88d0cd7a5659ff9748&mod=mw_quote_news
1 · Reply
Stengaard1
Stengaard1 Sep. 10 at 9:43 AM
$RENB Pay any attention to the messages Lunai has sent out the last weeks about regrouping in the US - and the numerous articles and filings about bioweapons. Lunai have secured two vital patents and have partnered up with ADI - I have a feeling that what we have seen so far is not the opening skirmishes. Don't be short...
0 · Reply
Stengaard1
Stengaard1 Sep. 9 at 9:37 PM
$RENB "This is all about understanding and predicting risk," said Dr. Gabe Musso, Chief Scientific Officer of Lunai Bioworks' wholly owned subsidiary Biosymetrics Inc. "Our platform accelerates the discovery of safe, effective therapeutics, with the added benefit of being able to safeguard against the creation of novel chemical threats. That's a major differentiator for our partners." https://www.myarklamiss.com/business/press-releases/accesswire/1070623/lunai-bioworks-inc-unveils-transformer-platform-to-secure-generative-ai-and-accelerate-drug-discovery/
0 · Reply
1dk2la
1dk2la Sep. 9 at 8:00 PM
$RENB volume is good, which is critical
1 · Reply
Sewdot
Sewdot Sep. 9 at 7:47 PM
$RENB let's goooooo
0 · Reply
Godsgrace2025
Godsgrace2025 Sep. 9 at 7:40 PM
$RENB God is good
0 · Reply
11thestate
11thestate Sep. 8 at 2:08 PM
$RENB has agreed to settle with $ENOB investors by paying $2.5 million to resolve claims that it concealed its co-founder’s lack of proper credentials and criminal history. Who’s eligible? Anyone who purchased $ENOB shares between January 17, 2018 and June 27, 2022. Do I need to sell my shares to qualify? No — you are eligible whether you sold your shares or still hold them. How much is the payout? The payout per share is $0.09 — but if only ~25% of eligible investors file, the effective payout could increase to $0.36. Can I still file? Yes — claims are currently being accepted. When do payouts happen? Typically within 8–12 months after court approval of the settlement. To file your claim: https://11th.com/cases/enochian-biosciences-investor-settlement?utm_source=stocktwits&utm_medium=referral&utm_campaign=faq&utm_content=09082025_1
1 · Reply
MarketForecasting
MarketForecasting Sep. 8 at 1:48 PM
$RENB a reverse split incoming 1-50 , company has no money , just filed bankruptcy, raised millions to avoid chapter 11. Easy easy short now or when rs comes .
0 · Reply
Stengaard1
Stengaard1 Sep. 8 at 1:08 PM
$RENB https://www.accessnewswire.com/newsroom/en/biotechnology/lunai-bioworks-strengthens-european-strategy-through-restructuring-1070014
0 · Reply
SameOldMan
SameOldMan Sep. 7 at 6:00 PM
$RENB Sbusidiary.... Yes, ENOCH merge/bought uot GEDI Cube Intl LTD on Feb 13, 2024; creating RENB. They are stated that they are not filing Bankruptcy and plan to "continue operating as usual." This is a setback. The short-term, more dillution is probably going to happen because of the funds they would have to settle to pay off debt. Their AI biodefense could be the solution to this will be in effect of long-term; but dillution will still be a issue. So, dillution and R/S will probably be the case of the future to sustain the company and complete their AI biodefense; or they can look for more sponsors to give them enough money to develop.
2 · Reply
SameOldMan
SameOldMan Sep. 7 at 5:51 PM
$RENB enovaro Biosciences ( RENB -3.23% ▼ ) just unveiled an announcement. On September 2, 2025, the Court of Amsterdam declared Gedi Cube B.V., an indirect subsidiary of Lunai Bioworks, Inc., bankrupt due to its inability to meet financial obligations. This development has led to a material impairment of assets for the company, which will be recorded in the quarter ending September 30, 2025. The company is assessing the impact on its supply chain and customer relationships and is implementing contingency plans to mitigate business disruptions. Lunai and its other subsidiaries continue to operate normally, with no bankruptcy filings. https://www.tipranks.com/news/company-announcements/renovaro-biosciences-faces-subsidiary-bankruptcy-impact#google_vignette
0 · Reply